CORAL GABLES, Fla., Nov. 8 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX - News) today announced the pricing of its initial public offering of 3,350,000 shares of common stock at a price to public of $6.00 per share. All shares are being offered by the Company. The Company’s common stock will trade on the Nasdaq Global Market under the trading symbol “CPRX.”
First Albany Capital, Inc. is acting as the sole book-running lead manager for the offering, and Stifel, Nicolaus & Company, Incorporated is acting as co-manager for the offering. The Company has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares to cover over- allotments, if any.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer or sale will be made only by means of the written prospectus forming a part of the effective registration statement. A copy of the prospectus relating to this offering may be obtained by contacting First Albany Capital, One Penn Plaza, 42nd Floor, New York, New York, 10119, or by calling (212) 273-7100.
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction.
Statements about the proposed offering are forward-looking statements as defined by the Securities and Exchange Commission. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors, many of which are outside of the control of the Company, and a variety of risks that could cause results to differ materially from those expected by the Company.
Source: Catalyst Pharmaceutical Partners, Inc.
